BR100 Decreased By (-0.1%)
BR30 Decreased By (-0.16%)
KSE100 Increased By (0.01%)
KSE30 Decreased By (-0.04%)
AGHA 7.83 Increased By ▲ 0.02 (0.26%)
BECO 5.17 Decreased By ▼ -0.04 (-0.77%)
BML 57.50 No Change ▼ 0.00 (0%)
BOP 33.95 Decreased By ▼ -0.08 (-0.24%)
CNERGY 9.96 No Change ▼ 0.00 (0%)
CSIL 5.40 Increased By ▲ 0.09 (1.69%)
FCCL 54.60 Decreased By ▼ -0.10 (-0.18%)
FFL 16.69 No Change ▼ 0.00 (0%)
FNEL 1.25 Increased By ▲ 0.02 (1.63%)
KEL 7.40 No Change ▼ 0.00 (0%)
KOSM 5.77 No Change ▼ 0.00 (0%)
LOTCHEM 29.20 Decreased By ▼ -0.12 (-0.41%)
MLCF 93.50 Decreased By ▼ -0.86 (-0.91%)
NBP 202.70 Decreased By ▼ -0.35 (-0.17%)
NCPL 56.99 Decreased By ▼ -0.01 (-0.02%)
NPL 67.92 Increased By ▲ 0.22 (0.32%)
OGDC 316.40 Increased By ▲ 0.56 (0.18%)
PACE 10.68 Increased By ▲ 0.04 (0.38%)
PAEL 43.41 Increased By ▲ 0.21 (0.49%)
PIBTL 16.75 Increased By ▲ 0.01 (0.06%)
PPL 219.40 Decreased By ▼ -0.38 (-0.17%)
PRL 49.30 Increased By ▲ 0.11 (0.22%)
PTC 71.02 Increased By ▲ 0.49 (0.69%)
SSGC 28.10 Decreased By ▼ -0.15 (-0.53%)
TBL 9.80 Decreased By ▼ -0.06 (-0.61%)
TELE 8.75 Decreased By ▼ -0.04 (-0.46%)
TPL 18.25 Increased By ▲ 0.01 (0.05%)
TPLP 13.58 Increased By ▲ 0.31 (2.34%)
TREET 22.73 Increased By ▲ 0.01 (0.04%)
TRG 60.50 Increased By ▲ 0.36 (0.6%)
World

S.Africa to resume J&J vaccinations

  • The vaccine was briefly put on hold after a handful of Americans developed blood clots.
Published Updated
By

JOHANNESBURG: South Africa announced Monday it would shortly resume using Johnson & Johnson anti-Covid vaccines, two weeks after the jab was suspended to vet risks over blood clots.

The vaccine will be included in South Africa's much-delayed anti-Covid vaccination campaign from Wednesday after being given the green light by SAHPRA, the country's health watchdog.

"It has since been established there is a one in a million chance of getting the clot after the vaccine and that it appears that women between the ages of 18 and 48 years old are particularly at risk," Health Minister Zwelini Mkhize said in a statement.

"With such a low probability of developing a clot, all the regulators across the world have recommended the continued use of Johnson and Johnson."

Many hopes have been staked on the Johnson & Johnson vaccine to roll back the pandemic in developing countries, as it is just a single-shot jab that does not need to be kept at ultra-low temperatures.

The vaccine was briefly put on hold after a handful of Americans developed blood clots.

According to US data presented Friday, of 3.9 million women who got the Johnson & Johnson shot, 15 developed serious blood clots and three died.

The majority of the confirmed cases, 13 of the 15, was aged under 50 years old. There were no reported cases among men.

The resumption of the Johnson & Johnson vaccine will target health workers in particular.

The authorities say they have purchased enough doses of the vaccine, as well as of Pfizer, to immunise at least 45 million people.

The deadline for achieving this has not been recently given. The government previously set a target of March 2022.

South Africa earlier this year purchased AstraZeneca vaccines and then sold them to other African countries following fears that it would be less effective against a local variant of coronavirus.

"It has been a difficult start for our country with the vaccination rollout, however despite all the challenges we have faced, we still have a positive outlook both for the recovery of public health and the economy at large," the minister said.

South Africa has officially recorded more than 1.5 million cases of Covid, of which 54,000 have been fatal.

The total number of people vaccinated, which used to be published daily by the ministry, has not been disclosed for several days.

Comments

Comments are closed for this article.